Immunological landscape of children with Mycoplasma pneumoniae pneumonia in the post-COVID-19 era reveals distinctive severity indicators

新冠疫情后时代,肺炎支原体肺炎患儿的免疫学特征揭示了其独特的严重程度指标。

阅读:2

Abstract

BACKGROUND: There is a recent global surge in Mycoplasma pneumoniae pneumonia (MPP). However, the key immune factors that contribute to the advancement of the disease remain unknown. Hence, we conducted this study to uncover the immunological profile in children affected by MPP. METHODS: This study enrolled children visiting Children's Hospital of Fudan University from December 2023 to April 2024, including 34 healthy controls, 51 severe MPP (S-MPP), 27 non-severe MPP (NS-MPP), and 34 non-MPP pneumonia (NMP) cases. Their blood samples were analyzed using flow cytometry, multi-cytokine assays, and antibody detection methods. RESULTS: Compared with NMP cases, MPP cases displayed higher frequencies of natural killer T cells, classical monocytes, and monocytic myeloid-derived suppressor cells. Notably, both T helper type 1 and activated regulatory T cells were more abundant in MPP cases, particularly in S-MPP, whereas CD8 + T cells displayed an exhaustion phenotype. The proportion of naïve B cells was reduced, while functional B cells, including memory B cells and plasmablasts, increased in S-MPP. 12 out of 95 clinical laboratory indicators and 3 out of 48 cytokines significantly differed between S-MPP and NS-MPP. Finally, we performed logistic and LASSO regression analyses and developed a predictive model for S-MPP that incorporates naïve B cell percentage from flow cytometry, cholinesterase from clinical laboratory tests, and interleukin 18 from the cytokine assay. CONCLUSIONS: These results clarify the immunological features in pediatric MPP cases, and identify novel markers for severe cases, providing insights for early diagnosis and immunological management in affected children.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。